Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362748 · ClinicalTrials.gov registry record · Phase 1
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04362748 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 34 participants.
The verdict
NCT04362748, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Interventions
- DRUG AMG 256
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362748
The ClinicalTrials.gov registry entry for NCT04362748 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 256 is the first listed.
NCT04362748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362748 about?
NCT04362748 is a clinical study titled "Study of AMG 256 in Adult Subjects With Advanced Solid Tumors". To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
What is the current status of trial NCT04362748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-09-15. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT04362748?
The interventions under investigation include: AMG 256 (DRUG).
Who is sponsoring clinical trial NCT04362748?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.